In a recent meta-analysis including patients with IBD treated with anti-TNF-α agents, the pooled incidence of any dermatological reaction was 19% (95% confidence interval (CI) 15–24), with psoriasis or psoriasiform rash being the most common [8]. The gene discussed is TNF; the disease is inflammatory bowel disease.